Prostate Cancer Foundation 2018 Scientific Retreat

Prostate Cancer Foundation 2018 Scientific Retreat

INTERVIEW WITH ANDREA MIYAHIRA
The Prostate Cancer Foundation: A Discussion with Andrea Miyahira

VIEW ALL PCF VIDEOS

Prostate Cancer Foundation 2018 Scientific Retreat

Prostate Cancer Foundation 2018 Scientific Retreat

INTERVIEW WITH KENNETH PIENTA
The Process of Metastasis in Prostate Cancer

VIEW ALL PCF VIDEOS

European Society for Medical Oncology 2018 Congress

European Society for Medical Oncology 2018 Congress

INTERVIEW WITH FRED SAAD
A Renewed Analysis of ERA 223

VIEW ALL ESMO VIDEOS

Videos
State-of-the-industry video lectures by leading urology experts
Latest Videos
Featured Videos

ORLANDO, FL USA (UroToday.com) - During the “Advanced Prostate Cancer II” session, Dr. Neal Shore presented further data from the ALSYMPCA trial. ALSYMPCA is a Phase 3 trial of Ra-223 for the treatment of symptomatic metastatic castrate-resistant prostate cancer (mCRPC) in patients with no known visceral mets. Ra-223, an alpha-emitting pharmaceutical, has been shown to significantly prolong overall survival and time to first symptomatic skeletal event, compared to placebo. Of the 921 patients randomized, 57% and 43% had prior or no prior docetaxel (D+/D-), respectively, and safety data from the predefined ALSYMPCA D subgroups were presented.

auaRegardless of D use, Ra-223 significantly prolonged overall survival (D+, HR = 0.70; D-, HR = 0.69). The risk of skeletal events was also reduced in the D+ and D- groups. D- patients did have lower rates of grade 3 or 4 anemia, neutropenia, and thrombocytopenia compared to the D+ group, but the overall frequency of grade 3 or 4 adverse events was low. A subgroup of 147 patients receiving chemotherapy after Ra-223 demonstrated comparable rates of grade 3 or 4 anemia and neutropenia between D+ and D- groups.

Dr. Shore concluded that Ra-223 significantly prolongs OS with a favorable safety profile in mCRPC patients with symptomatic bone metastases regardless of D use. Rates of grade 3 or 4 hematologic adverse events were slightly higher in D+ patients.

Click HERE to view the poster from this session

Presented by Neal D. Shore, MD, FACS at the American Urological Association (AUA) Annual Meeting - May 16 - 21, 2014 - Orlando, Florida USA

Myrtle Beach, SC USA

Written by Jeffrey J. Tomaszewski, MD, medical writer for UroToday.com

 

 

Clinical Trials
Searchable data base of currently enrolling clinical trials
Journals
Publications focusing on urological cancer treatments through original commentary & articles
Everyday Urology Volume 3 Issue 3

Everyday Urology™ - Oncology Insights

PCAN cover

Prostate Cancer and Prostatic Diseases

From the Editor

@UroToday
E-Newsletters

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.

Subscribe

Calendar
Upcoming educational events
December 13-16, 2018 / ESMO Immuno-Oncology Congress 2018
ESMO Immuno-Oncology Congress 2018
January 17-19, 2019 /
SNMMI 2019 Mid-Winter Meeting